
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MT1013
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Shaanxi Micot Technology Limited Company
Deal Size : Inapplicable
Deal Type : Inapplicable
MT1013 Clinical TRIAL In Healthy Subject
Details : MT1013 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : MT1013
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Shaanxi Micot Technology Limited Company
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IMT-002
Therapeutic Area : Endocrinology
Study Phase : Phase I
Recipient : ImmunoMolecular Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes
Details : IMT-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2020
Lead Product(s) : IMT-002
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : ImmunoMolecular Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Stanford University | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 27, 2019
Lead Product(s) : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Stanford University | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Norwalk GI.1 Virus
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Vaxart
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Norwalk GI.1 Virus is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Caliciviridae Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 26, 2018
Lead Product(s) : Norwalk GI.1 Virus
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Vaxart
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Insulin Lispro
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Dance Biopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Human Insulin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 11, 2017
Lead Product(s) : Insulin Lispro
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Dance Biopharm
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris
Details : SB204 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 16, 2016
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PUL-042
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Pulmotect
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PUL-042 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 02, 2015
Lead Product(s) : PUL-042
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Pulmotect
Deal Size : Inapplicable
Deal Type : Inapplicable

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)
Details : NGP 555 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 02, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MOD-4023
Therapeutic Area : Endocrinology
Study Phase : Phase I
Recipient : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MOD-4023 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dwarfism, Pituitary.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 16, 2015
Lead Product(s) : MOD-4023
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
